ReviewJournal of Parkinson's disease2026
Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review.
Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCognitive impairment and neuropsychiatric manifestations are common disabling non-motor symptoms that can negatively impact quality of life in Parkinson's disease. This review aimed to critically appraise and synthesize evidence on the prevalence, predictors, and emerging biomarkers of cognitive impairment and neuropsychiatric manifestations among patients with Parkinson's disease in Africa.MethodsWe conducted a systematic review of studies reporting cognitive and neuropsychiatric outcomes among individuals with Parkinson's disease in African populations, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We used the Critical Appraisal Skills Program checklist to determine the quality of the included studies. The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to estimate the certainty of the evidence.ResultsA total of 32 studies, including 3687 patients, were analyzed. The prevalence of cognitive impairment ranged from 21.6% to 92%. Depression was the most common neuropsychiatric symptom (up to 81.7%). Consistent predictors of cognitive impairment included older age, advanced disease, and greater motor severity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.